TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
MWN-AI** Summary
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies, recently announced significant outsourcing initiatives aimed at reducing its operational burn rate and overall overhead. The company revealed that it is shifting towards a more decentralized model, which involves the transition to a Contract Development and Manufacturing Organization (CDMO) model for production. This strategic change is expected to facilitate a larger production capacity for upcoming clinical trials and incorporate advanced manufacturing technologies.
As part of this restructuring, TCB has indicated a workforce reduction of around 20 employees, primarily within its production and quality divisions, which represents nearly half of the company's total headcount. The company anticipates that these changes will culminate by the end of the second quarter of 2025. When compared to 2024, the adjustments are expected to result in a 55% reduction in core operational burn, contributing to estimated savings of approximately $2.1 million for the partial year of 2025, and annualized savings of around $4.2 million.
CEO Bryan Kobel emphasized the necessity of these changes to better position TC BioPharm for future clinical trial pathways and to enhance the efficiency of its operations. He acknowledged the emotional toll of staff reductions but expressed gratitude for the contributions of those departing.
TC BioPharm is a pioneer in the field of gamma-delta T cell therapies, having conducted the first phase II pivotal clinical trials in oncology. The company aims to utilize this outsourcing approach to strengthen its foundation and continue to innovate in the development of treatments for cancer.
MWN-AI** Analysis
TC BioPharm (NASDAQ: TCBP) has recently announced a strategic shift towards outsourcing key functions, which aims to drastically cut its operational burn rate by approximately 55% by the end of 2025. This initiative, while challenging, positions the company to better navigate the complexities of clinical-stage biopharmaceutical development, particularly in the burgeoning sector of gamma-delta T cell therapies for cancer.
By transitioning to a Contract Development and Manufacturing Organization (CDMO) model, TCBP can mitigate costs associated with in-house production and quality oversight, which currently contribute significantly to its overhead. The anticipated savings of around $4.2 million annually, combined with the workforce reduction (effectively halving total headcount), reflects a decisive move to enhance operational efficiency. This pragmatic approach not only streamlines expenditures but also promises to bolster the company’s competitive advantage as it prepares for critical clinical trials and data reviews in 2025.
Investors should consider the potential positive impact of these measures on TCBP's long-term viability and the future pipeline of clinical trials. By focusing on advanced manufacturing techniques, TC BioPharm could swiftly adapt to the evolving demands of the biotechnology landscape, further opening pathways to partnerships with established firms in drug development.
However, the market should be cautious. While the outsourcing initiative is aimed at solidifying TCBP's financial health, execution risks remain. Any disruptions in the transition process or challenges with CDMO partnerships could affect clinical timelines and, ultimately, investor confidence. It is crucial for stakeholders to monitor not only the operational outcomes of these initiatives but also how the market perceives the company’s strategic pivot.
In summary, TCBP's outsourcing strategy could enhance its fiscal stability and operational agility, making it an interesting prospect for investors seeking exposure in the biotech sector, albeit with an awareness of associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- The company is expected to reduce core operational burn by 55% when compared to 2024
EDINBURGH, Scotland , March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan.
The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and other cell therapy production technologies. Additionally, the company is reviewing alternative approaches for testing and clinical needs, which align with a decentralized drug development model. This approach is expected to result in a workforce reduction of approximately 20 employees, focused largely within the company's production and quality divisions and represents approximately half of the company's total headcount. Separations will be substantially complete by the end of the second quarter 2025 and are expected to reduce the core operational burn rate by approximately 55% compared to 2024.? As a result of these steps, when compared to 2024, the Company estimates partial year 2025 savings to be approximately $2.1 million and annualized savings to be roughly $4.2 million.
"This decision to reduce staff is attributable to the company's strategic shift in focus towards an outsourced production model and something that we believe will ultimately better position TC BioPharm for future clinical trial plans as well as advancements in new cell therapy manufacturing technologies," said Bryan Kobel , CEO of TC BioPharm. "We are at a pivotal moment in our development as we expand into new indication verticals, prepare for ACHIEVE data review which will drive our next clinical pathway, and reduce the need for costly in-house expenses to provide a stronger foundation for future growth. I arrived at this decision knowing it will be difficult to say goodbye to colleagues who have been a significant part of TC BioPharm's culture and accomplishments. I'm grateful to all those who have shared in our history and to those who will continue to usher in the next phase of TCBP."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b /3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 , and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov . All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
SOURCE TC BioPharm
FAQ**
How does TC BioPharm (Holdings) plc TCBP plan to identify and select the CDMO partners for its new outsourced production model, and what criteria will be used to ensure quality and efficiency?
What specific measures will TC BioPharm (Holdings) plc TCBP take to maintain its organizational culture after reducing its workforce by 50% in its production and quality divisions?
How will the anticipated savings of approximately $4.2 million annually from the restructuring initiatives impact TC BioPharm (Holdings) plc TCBP's future research and clinical trial funding?
What risks and challenges does TC BioPharm (Holdings) plc TCBP foresee in transitioning to a decentralized drug development model while preparing for the ACHIEVE data review?
**MWN-AI FAQ is based on asking OpenAI questions about TC BioPharm (Holdings) plc (NASDAQ: TCBP).
NASDAQ: TCBP
TCBP Trading
-202.0% G/L:
$0.50 Last:
5,896,474 Volume:
$1.51 Open:
